phosphonoacetic acid has been researched along with Herpes Simplex in 80 studies
Phosphonoacetic Acid: A simple organophosphorus compound that inhibits DNA polymerase, especially in viruses and is used as an antiviral agent.
phosphonoacetic acid : A member of the class of phosphonic acids that is phosphonic acid in which the hydrogen attached to the phosphorous is replaced by a carboxymethyl group.
Herpes Simplex: A group of acute infections caused by herpes simplex virus type 1 or type 2 that is characterized by the development of one or more small fluid-filled vesicles with a raised erythematous base on the skin or mucous membrane. It occurs as a primary infection or recurs due to a reactivation of a latent infection. (Dorland, 27th ed.)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Herpes simplex virus (HSV) resistant to acyclovir can produce persistent mucocutaneous ulcerative disease in patients with the acquired immunodeficiency syndrome (AIDS)." | 9.07 | Foscarnet treatment of acyclovir-resistant herpes simplex virus infection in patients with acquired immunodeficiency syndrome: preliminary results of a controlled, randomized, regimen-comparative trial. ( Hardy, WD, 1992) |
| "Acyclovir can prevent the establishment of latent herpes simplex virus (HSV) in sensory ganglia by early treatment of the primary infection in experimental animals." | 8.76 | Treatment of experimental latent herpes simplex virus infections with acyclovir and other antiviral compounds. ( Klein, RJ, 1982) |
| "The role of acyclovir-sensitive herpes simplex virus (HSV) was analyzed in the process of its replacement by a resistant virus in vitro and in vivo in the aspect of acyclovir therapy." | 7.72 | Suppression of generation and replication of acyclovir-resistant herpes simplex virus by a sensitive virus. ( Honda, M; Kurokawa, M; Matsuo, K; Niimura, M; Okuda, T; Shiraki, K, 2004) |
| "Eugeniin exhibits antiviral activity against acyclovir and phosphonoacetic acid (PAA)-resistant herpes simplex virus type 1 (HSV-1) as well as the wild-type HSV-1 in vitro." | 7.71 | Biological characterization of eugeniin as an anti-herpes simplex virus type 1 compound in vitro and in vivo. ( Hozumi, T; Kadota, S; Kurokawa, M; Namba, T; Shiraki, K; Tsurita, M, 2001) |
| "Mucocutaneous herpes simplex virus (HSV) infections that are resistant to therapy with acyclovir have been recognized with increasing frequency in patients with the acquired immunodeficiency syndrome, although alternative therapies in this setting have not been widely studied." | 7.68 | Foscarnet therapy for acyclovir-resistant mucocutaneous herpes simplex virus infection in 26 AIDS patients: preliminary data. ( Assaykeen, T; Follansbee, S; Mills, J; Safrin, S, 1990) |
| "Three marrow transplant patients developed pneumonia due to acyclovir-resistant thymidine-kinase-deficient herpes simplex virus (HSV) type 1." | 7.68 | Acyclovir-resistant herpes simplex virus causing pneumonia after marrow transplantation. ( Ellis, MN; Hackman, RC; Ljungman, P; Meyers, JD; Shepp, DH, 1990) |
| "Foscarnet (trisodium phosphonoformate), an investigational pyrophosphate analog increasingly used to treat refractory cytomegalovirus retinitis and mucocutaneous herpes simplex virus infections in immunocompromised patients, has been reported to cause abnormalities in serum calcium and phosphate, including cases of fatal hypocalcemia." | 7.68 | Foscarnet-induced hypocalcemia and effects of foscarnet on calcium metabolism. ( Aweeka, FT; Causey, DM; Gambertoglio, JG; Jacobson, MA; Portale, AA, 1991) |
| "Resistance of herpes simplex virus to acyclovir is a problem of growing clinical importance." | 7.68 | Heterogeneity of a herpes simplex virus clinical isolate exhibiting resistance to acyclovir and foscarnet. ( Coen, DM; Hicks, KA; Pelosi, E; Sacks, SL, 1992) |
| "To determine whether trisodium phosphonoformate (foscarnet) is efficacious in treating severe mucocutaneous disease due to acyclovir-resistant herpes simplex virus type-2 (HSV-2) infection in patients with the acquired immunodeficiency syndrome (AIDS)." | 7.67 | Foscarnet therapy for severe acyclovir-resistant herpes simplex virus type-2 infections in patients with the acquired immunodeficiency syndrome (AIDS). An uncontrolled trial. ( Drennan, DP; Erlich, KS; Follansbee, SE; Gooze, L; Jacobson, MA; Koehler, JE; Mills, J; Safrin, S, 1989) |
| "Methoxymethyldeoxyuridine (MMUdR) when used in combination with either trifluorothymidine (F3TdR) or phosphonoformate (PFA) showed synergistic activity against herpes simplex virus type 1 and type 2 (HSV-1 and HSV-2) in vitro, whereas MMUdR and acycloguanosine (ACG) combination was antagonistic against herpes viruses." | 7.67 | Combination chemotherapy: interaction of 5-methoxymethyldeoxyuridine with trifluorothymidine, phosphonoformate and acycloguanosine against herpes simplex viruses. ( Ayisi, NK; Babiuk, LA; Gupta, SV, 1985) |
| "Topical foscarnet (PFA) and acyclovir (ACV) were compared in the dorsal cutaneous guinea pig model of herpes simplex virus type 1 infection." | 7.67 | Comparison of foscarnet cream, acyclovir cream, and acyclovir ointment in the topical treatment of experimental cutaneous herpes simplex virus type 1 infection. ( Freeman, DJ; Sheth, NV; Spruance, SL, 1986) |
| "The sensitivity of different herpes simplex virus type 2 (HSV-2) strains to inhibition by 5-vinyl-1-beta-D-arabinofuranosyluracil (VaraU) was evaluated in comparison to 9-(2-hydroxyethoxymethyl)guanine (ACV; acyclovir) and trisodiumphosphonoformate (Na3PFA; foscarnet), using a plaque inhibition assay in primary rabbit testes (PRT) cells as well as in human embryonic lung fibroblast (HELF) cell cultures." | 7.67 | Efficacy of 5-vinyl-1-beta-D-arabinofuranosyluracil (VaraU) against herpes simplex virus type 2 strains in cell cultures and against experimental herpes encephalitis in mice: comparison with acyclovir and foscarnet. ( Herrmann, G; Reefschläger, J; Thiel, KD; Wutzler, P, 1987) |
| "The influence of (E)-5-(2-bromovinyl)-2'-deoxyuridine (BVDU), caffeic acid oxidation product (KOP), and trisodiumphosphonoformate (TPF) on the course of the primary cutaneous herpes simplex virus infection was investigated by means of a guinea pig test model." | 7.67 | Therapeutic effect of (E)-5-(2-bromovinyl)-2'-deoxyuridine, caffeic acid oxidation product, and trisodiumphosphonoformate on cutaneous herpes simplex virus type 1 infection in guinea pigs. ( Helbig, B; Herrmann, G; Klöcking, R; Sauerbrei, A; Wicht, N; Wiedemann, U; Wutzler, P, 1987) |
| "The efficiency of (E)-5-(2-bromovinyl)- and 5-vinyl-1-beta-D-arabinofuranosyluracil (BrVaraU, VaraU) as inhibitors of three herpes simplex virus type 1 (HSV-1) strains was assessed in comparison to (E)-5-(2-bromovinyl)-2'-deoxyuridine (BrVUdR), 9-(2-hydroxyethoxymethyl)guanine (ACV), and trisodium phosphonoformate (Na3PFA) using a plaque assay in human embryonic lung fibroblast (HELF) cell cultures." | 7.67 | Treatment of experimental herpes simplex virus type 1 encephalitis in mice with (E)-5-(2-bromovinyl)- and 5-vinyl-1-beta-D-arabinofuranosyluracil: comparison with bromovinyl-deoxyuridine and acyclovir. ( Herrmann, G; Reefschläger, J; Thiel, KD; Wutzler, P, 1986) |
| "Rapidly progressive disease due to acyclovir-resistant herpes simplex has not been described." | 7.67 | Progressive mucocutaneous herpes simplex infection due to acyclovir-resistant virus in an immunocompromised patient: correlation of viral susceptibilities and plasma levels with response to therapy. ( Bean, B; Ellis, MN; Englund, J; Fletcher, C; Lehrman, SN, 1987) |
| "The inhibition by acyclovir of the in vitro reactivation of herpes simplex virus from latently infected ganglion explant cultures is dependent on the continuous presence of this drug." | 7.66 | Effect of acyclovir on latent herpes simplex virus infections in trigeminal ganglia of mice. ( Brady, E; DeStefano, E; Friedman-Kien, AE; Klein, RJ, 1981) |
| "The antiviral activity of 5-methoxymethyl-2'-deoxyuridine (MMUdR) was compared with that of 5-iodo-2'-deoxyuridine (IUdR), 5-ethyl-2'-deoxyuridine (EtUdR), adenine arabinoside (Ara-A), and phosphonoacetic acid (PAA) against herpes simplex virus type 1 (HSV-1) and type 2 (HSV-2)." | 7.66 | Combination chemotherapy: interaction of 5-methoxymethyldeoxyuridine with adenine arabinoside, 5-ethyldeoxyuridine, 5-iododeoxyuridine, and phosphonoacetic acid against herpes simplex virus types 1 and 2. ( Ayisi, NK; Babiuk, LA; Gupta, VS; Meldrum, JB; Taneja, AK, 1980) |
| "Skin infections induced in hairless mice with an Acyclovir resistant herpes simplex virus (HSV) mutant were not followed by the death of the animals, and the survivors had no evidence of latent infections in their sensory ganglia." | 7.66 | Experimental skin infection with an acyclovir resistant herpes simplex virus mutant: response to antiviral treatment and protection against reinfection. ( Brady, E; DeStefano, E; Friedman-Kien, AE; Klein, RJ, 1980) |
| "The therapeutic effects of topically applied foscarnet sodium and acyclovir on cutaneous infections due to herpes simplex virus type 1 (HSV-1) were studied in guinea pigs." | 7.66 | Therapeutic effects of foscarnet sodium and acyclovir on cutaneous infections due to herpes simplex virus type 1 in guinea pigs. ( Alenius, S; Berg, M; Broberg, F; Eklind, K; Lindborg, B; Oberg, B, 1982) |
| "An acyclovir-resistant herpes simplex virus (HSV) has been isolated from an immunocompromised patient during treatment for severe orofacial HSV infections with acyclovir." | 7.66 | Drug-resistant herpes simplex virus in vitro and after acyclovir treatment in an immunocompromised patient. ( Crumpacker, CS; Hershey, BJ; Kowalsky, P; Levin, MJ; Marlowe, SI; Schnipper, LE, 1982) |
| "Phosphonoacetic acid (PAA) was evaluated as therapy for primary cutaneous herpes simplex virus (HSV) infections in guinea pigs." | 7.66 | Topical phosphonoacetic acid treatment of cutaneous herpes simplex infections in the guinea pig. ( Jarratt, MT; McCarty, JR, 1979) |
| "Virus isolates from four AIDS patients and one bone marrow transplant recipient were examined for their sensitivity for the antiviral compounds used by means of plaque reduction assay." | 5.28 | [Acyclovir-resistant herpes simplex virus infections in immunocompromised patients]. ( Frissen, PH; Jansen, CL; Maris-Tegeler, WG; van der Noordaa, J; Weiland, HT; Wertheim-van Dillen, PM, 1992) |
| "Herpes simplex virus (HSV) resistant to acyclovir can produce persistent mucocutaneous ulcerative disease in patients with the acquired immunodeficiency syndrome (AIDS)." | 5.07 | Foscarnet treatment of acyclovir-resistant herpes simplex virus infection in patients with acquired immunodeficiency syndrome: preliminary results of a controlled, randomized, regimen-comparative trial. ( Hardy, WD, 1992) |
| "Acyclovir can prevent the establishment of latent herpes simplex virus (HSV) in sensory ganglia by early treatment of the primary infection in experimental animals." | 4.76 | Treatment of experimental latent herpes simplex virus infections with acyclovir and other antiviral compounds. ( Klein, RJ, 1982) |
| " A MeOH extract of Symphyocladia latiuscula (Rhodomelaceae) and its fractions exhibited antiviral activities against acyclovir (ACV) and phosphonoacetic acid (PAA)-resistant (AP(r)) herpes simplex type 1 (HSV-1), thymidine kinase (TK(-)) deficient HSV-1 and wild type HSV-1 in vitro without cytotoxicity." | 3.73 | Antiviral activity of the marine alga Symphyocladia latiuscula against herpes simplex virus (HSV-1) in vitro and its therapeutic efficacy against HSV-1 infection in mice. ( Choi, JS; Hattori, M; Kurokawa, M; Nakamura, N; Park, HJ; Shiraki, K, 2005) |
| "The role of acyclovir-sensitive herpes simplex virus (HSV) was analyzed in the process of its replacement by a resistant virus in vitro and in vivo in the aspect of acyclovir therapy." | 3.72 | Suppression of generation and replication of acyclovir-resistant herpes simplex virus by a sensitive virus. ( Honda, M; Kurokawa, M; Matsuo, K; Niimura, M; Okuda, T; Shiraki, K, 2004) |
| "Eugeniin exhibits antiviral activity against acyclovir and phosphonoacetic acid (PAA)-resistant herpes simplex virus type 1 (HSV-1) as well as the wild-type HSV-1 in vitro." | 3.71 | Biological characterization of eugeniin as an anti-herpes simplex virus type 1 compound in vitro and in vivo. ( Hozumi, T; Kadota, S; Kurokawa, M; Namba, T; Shiraki, K; Tsurita, M, 2001) |
| "Mucocutaneous herpes simplex virus (HSV) infections that are resistant to therapy with acyclovir have been recognized with increasing frequency in patients with the acquired immunodeficiency syndrome, although alternative therapies in this setting have not been widely studied." | 3.68 | Foscarnet therapy for acyclovir-resistant mucocutaneous herpes simplex virus infection in 26 AIDS patients: preliminary data. ( Assaykeen, T; Follansbee, S; Mills, J; Safrin, S, 1990) |
| "Three AIDS patients with severe cutaneous herpes simplex virus (HSV) infection refractory to therapy with acyclovir and foscarnet (2 patients) were treated with a topical preparation of trifluorothymidine (TFT) and interferon-alpha." | 3.68 | Clinical effects and in vitro studies of trifluorothymidine combined with interferon-alpha for treatment of drug-resistant and -sensitive herpes simplex virus infections. ( Birch, CJ; Doherty, R; Hayes, K; Lucas, CR; Mijch, A; Tachedjian, G; Tyssen, DP, 1992) |
| "Three marrow transplant patients developed pneumonia due to acyclovir-resistant thymidine-kinase-deficient herpes simplex virus (HSV) type 1." | 3.68 | Acyclovir-resistant herpes simplex virus causing pneumonia after marrow transplantation. ( Ellis, MN; Hackman, RC; Ljungman, P; Meyers, JD; Shepp, DH, 1990) |
| "Acyclovir (ACV)-resistant herpes simplex virus type 2 (HSV-2) was isolated from a patient with acquired immunodeficiency syndrome after long-term but intermittent ACV therapy." | 3.68 | Altered sensitivity to antiviral drugs of herpes simplex virus isolates from a patient with the acquired immunodeficiency syndrome. ( Birch, CJ; Doherty, RR; Gust, ID; Hayes, K; Tachedjian, G, 1990) |
| "Foscarnet (trisodium phosphonoformate), an investigational pyrophosphate analog increasingly used to treat refractory cytomegalovirus retinitis and mucocutaneous herpes simplex virus infections in immunocompromised patients, has been reported to cause abnormalities in serum calcium and phosphate, including cases of fatal hypocalcemia." | 3.68 | Foscarnet-induced hypocalcemia and effects of foscarnet on calcium metabolism. ( Aweeka, FT; Causey, DM; Gambertoglio, JG; Jacobson, MA; Portale, AA, 1991) |
| "Resistance of herpes simplex virus to acyclovir is a problem of growing clinical importance." | 3.68 | Heterogeneity of a herpes simplex virus clinical isolate exhibiting resistance to acyclovir and foscarnet. ( Coen, DM; Hicks, KA; Pelosi, E; Sacks, SL, 1992) |
| "The herpesvirus DNA polymerase inhibitor foscarnet, applied topically, and the anti-herpesvirus guanosine analogue buciclovir, given orally, decreased virus replication and disease development in primary skin infections of mice caused by herpes simplex virus type 1 (HSV-1)." | 3.67 | Limited efficacy of inhibitors of herpes simplex virus DNA synthesis in murine models of recrudescent disease. ( Datema, R; Ericson, AC; Kristofferson, A; Sohl-Akerlund, A, 1988) |
| "The sensitivity of different herpes simplex virus type 2 (HSV-2) strains to inhibition by 5-vinyl-1-beta-D-arabinofuranosyluracil (VaraU) was evaluated in comparison to 9-(2-hydroxyethoxymethyl)guanine (ACV; acyclovir) and trisodiumphosphonoformate (Na3PFA; foscarnet), using a plaque inhibition assay in primary rabbit testes (PRT) cells as well as in human embryonic lung fibroblast (HELF) cell cultures." | 3.67 | Efficacy of 5-vinyl-1-beta-D-arabinofuranosyluracil (VaraU) against herpes simplex virus type 2 strains in cell cultures and against experimental herpes encephalitis in mice: comparison with acyclovir and foscarnet. ( Herrmann, G; Reefschläger, J; Thiel, KD; Wutzler, P, 1987) |
| "Topical foscarnet (PFA) and acyclovir (ACV) were compared in the dorsal cutaneous guinea pig model of herpes simplex virus type 1 infection." | 3.67 | Comparison of foscarnet cream, acyclovir cream, and acyclovir ointment in the topical treatment of experimental cutaneous herpes simplex virus type 1 infection. ( Freeman, DJ; Sheth, NV; Spruance, SL, 1986) |
| "The influence of (E)-5-(2-bromovinyl)-2'-deoxyuridine (BVDU), caffeic acid oxidation product (KOP), and trisodiumphosphonoformate (TPF) on the course of the primary cutaneous herpes simplex virus infection was investigated by means of a guinea pig test model." | 3.67 | Therapeutic effect of (E)-5-(2-bromovinyl)-2'-deoxyuridine, caffeic acid oxidation product, and trisodiumphosphonoformate on cutaneous herpes simplex virus type 1 infection in guinea pigs. ( Helbig, B; Herrmann, G; Klöcking, R; Sauerbrei, A; Wicht, N; Wiedemann, U; Wutzler, P, 1987) |
| "Methoxymethyldeoxyuridine (MMUdR) when used in combination with either trifluorothymidine (F3TdR) or phosphonoformate (PFA) showed synergistic activity against herpes simplex virus type 1 and type 2 (HSV-1 and HSV-2) in vitro, whereas MMUdR and acycloguanosine (ACG) combination was antagonistic against herpes viruses." | 3.67 | Combination chemotherapy: interaction of 5-methoxymethyldeoxyuridine with trifluorothymidine, phosphonoformate and acycloguanosine against herpes simplex viruses. ( Ayisi, NK; Babiuk, LA; Gupta, SV, 1985) |
| "Several 5-methoxymethyldeoxyuridine (MMdU)-resistant mutants of herpes simplex virus type 1 (HSV1) were classified by measuring their sensitivities to the deoxythymidine kinase (dTK)-dependent antiviral drugs 9-(2-hydroxyethoxymethyl)-guanine (acyclovir, ACV), 1-beta-D-arabinofuranosylthymine (araT), and E-(2)-5-bromovinyldeoxyuridine (BVdU) and to the dTK-independent antiviral drug phosphonoacetate (PAA)." | 3.67 | HSV1-specific thymidylate kinase activity in infected cells. ( Gentry, GA; Veerisetty, V, 1985) |
| "The efficiency of (E)-5-(2-bromovinyl)- and 5-vinyl-1-beta-D-arabinofuranosyluracil (BrVaraU, VaraU) as inhibitors of three herpes simplex virus type 1 (HSV-1) strains was assessed in comparison to (E)-5-(2-bromovinyl)-2'-deoxyuridine (BrVUdR), 9-(2-hydroxyethoxymethyl)guanine (ACV), and trisodium phosphonoformate (Na3PFA) using a plaque assay in human embryonic lung fibroblast (HELF) cell cultures." | 3.67 | Treatment of experimental herpes simplex virus type 1 encephalitis in mice with (E)-5-(2-bromovinyl)- and 5-vinyl-1-beta-D-arabinofuranosyluracil: comparison with bromovinyl-deoxyuridine and acyclovir. ( Herrmann, G; Reefschläger, J; Thiel, KD; Wutzler, P, 1986) |
| "To determine whether trisodium phosphonoformate (foscarnet) is efficacious in treating severe mucocutaneous disease due to acyclovir-resistant herpes simplex virus type-2 (HSV-2) infection in patients with the acquired immunodeficiency syndrome (AIDS)." | 3.67 | Foscarnet therapy for severe acyclovir-resistant herpes simplex virus type-2 infections in patients with the acquired immunodeficiency syndrome (AIDS). An uncontrolled trial. ( Drennan, DP; Erlich, KS; Follansbee, SE; Gooze, L; Jacobson, MA; Koehler, JE; Mills, J; Safrin, S, 1989) |
| "Rapidly progressive disease due to acyclovir-resistant herpes simplex has not been described." | 3.67 | Progressive mucocutaneous herpes simplex infection due to acyclovir-resistant virus in an immunocompromised patient: correlation of viral susceptibilities and plasma levels with response to therapy. ( Bean, B; Ellis, MN; Englund, J; Fletcher, C; Lehrman, SN, 1987) |
| "The antiviral activity of 5-methoxymethyl-2'-deoxyuridine (MMUdR) was compared with that of 5-iodo-2'-deoxyuridine (IUdR), 5-ethyl-2'-deoxyuridine (EtUdR), adenine arabinoside (Ara-A), and phosphonoacetic acid (PAA) against herpes simplex virus type 1 (HSV-1) and type 2 (HSV-2)." | 3.66 | Combination chemotherapy: interaction of 5-methoxymethyldeoxyuridine with adenine arabinoside, 5-ethyldeoxyuridine, 5-iododeoxyuridine, and phosphonoacetic acid against herpes simplex virus types 1 and 2. ( Ayisi, NK; Babiuk, LA; Gupta, VS; Meldrum, JB; Taneja, AK, 1980) |
| "Skin infections induced in hairless mice with an Acyclovir resistant herpes simplex virus (HSV) mutant were not followed by the death of the animals, and the survivors had no evidence of latent infections in their sensory ganglia." | 3.66 | Experimental skin infection with an acyclovir resistant herpes simplex virus mutant: response to antiviral treatment and protection against reinfection. ( Brady, E; DeStefano, E; Friedman-Kien, AE; Klein, RJ, 1980) |
| "The inhibition by acyclovir of the in vitro reactivation of herpes simplex virus from latently infected ganglion explant cultures is dependent on the continuous presence of this drug." | 3.66 | Effect of acyclovir on latent herpes simplex virus infections in trigeminal ganglia of mice. ( Brady, E; DeStefano, E; Friedman-Kien, AE; Klein, RJ, 1981) |
| "The comparative analysis of the pathogenicity of a parental herpes simplex virus type 1 strain and its phosphonoacetic acid (PAA)-resistant and acyclovir (ACV)-resistant mutants showed marked differences among them." | 3.66 | Pathogenesis of experimental skin infections induced by drug-resistant herpes simplex virus mutants. ( DeStefano, E; Friedman-Kien, AE; Klein, RJ, 1981) |
| "The therapeutic effects of topically applied foscarnet sodium and acyclovir on cutaneous infections due to herpes simplex virus type 1 (HSV-1) were studied in guinea pigs." | 3.66 | Therapeutic effects of foscarnet sodium and acyclovir on cutaneous infections due to herpes simplex virus type 1 in guinea pigs. ( Alenius, S; Berg, M; Broberg, F; Eklind, K; Lindborg, B; Oberg, B, 1982) |
| "Phosphonoacetic acid (PAA) was evaluated as therapy for primary cutaneous herpes simplex virus (HSV) infections in guinea pigs." | 3.66 | Topical phosphonoacetic acid treatment of cutaneous herpes simplex infections in the guinea pig. ( Jarratt, MT; McCarty, JR, 1979) |
| "An acyclovir-resistant herpes simplex virus (HSV) has been isolated from an immunocompromised patient during treatment for severe orofacial HSV infections with acyclovir." | 3.66 | Drug-resistant herpes simplex virus in vitro and after acyclovir treatment in an immunocompromised patient. ( Crumpacker, CS; Hershey, BJ; Kowalsky, P; Levin, MJ; Marlowe, SI; Schnipper, LE, 1982) |
| " These questions concern appropriate routes of administration for antiviral compounds, optimal dosage regimens, risks of long-term prophylaxis, and the emergence of resistant organisms." | 2.66 | Antiviral chemotherapy and chemoprophylaxis. ( Dolin, R, 1985) |
| " Myelosuppression may be further exacerbated in AIDS patients by such other agents as zidovudine or trimethoprim/sulfamethoxazole, often necessitating dosage reductions or discontinuation of these agents in patients receiving ganciclovir." | 2.38 | Foscarnet sodium. ( Baltz, JK; Minor, JR, 1991) |
| "Acyclovir is a prototype of this improved process." | 2.37 | Promising new antiviral drugs. ( Bryson, YJ, 1988) |
| "The mechanism of recurrence is yet not fully elucidated and therapy still remains a problem." | 2.36 | [Herpes simplex]. ( Fanta, D, 1981) |
| "Virus isolates from four AIDS patients and one bone marrow transplant recipient were examined for their sensitivity for the antiviral compounds used by means of plaque reduction assay." | 1.28 | [Acyclovir-resistant herpes simplex virus infections in immunocompromised patients]. ( Frissen, PH; Jansen, CL; Maris-Tegeler, WG; van der Noordaa, J; Weiland, HT; Wertheim-van Dillen, PM, 1992) |
| "Phosphonoacetic acid is a selective antiherpesvirus agent." | 1.27 | Structure-activity studies on phosphonoacetate. ( Duff, RG; Fairgrieve, JS; Herrin, TR; Mao, JC; Otis, ER; Shipkowitz, NL; von Esch, AM, 1985) |
| " The dosage of Foscarnet was increased during the study." | 1.27 | Clinical experiences with phosphonoformate (foscarnet) treatment of viral diseases following renal transplantation. ( Ahlmén, J; Brynger, H; Lycke, E; Wijnween, AC, 1985) |
| "Phosphonoacetic acid was the only compound with a good therapeutic activity against herpesvirus infection, causing a reduction of both the cumulative score and the time to healing." | 1.26 | Comparison of the therapeutic effects of five antiviral agents on cutaneous herpesvirus infection in guinea pigs. ( Alenius, S; Oberg, B, 1978) |
| "Phosphonoacetic acid was highly effective in preventing the development of skin lesions, and no latent infections were detected when phosphonoacetic acid ointment was applied 3 h after infection." | 1.26 | Orofacial herpes simplex virus infection in hairless mice: latent virus in trigeminal ganglia after topical antiviral treatment. ( Friedman-Kien, AE; Klein, RJ; Yellin, PB, 1978) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 50 (62.50) | 18.7374 |
| 1990's | 22 (27.50) | 18.2507 |
| 2000's | 6 (7.50) | 29.6817 |
| 2010's | 2 (2.50) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Griengl, H | 1 |
| Hayden, W | 1 |
| Penn, G | 1 |
| De Clercq, E | 1 |
| Rosenwirth, B | 1 |
| Diana, GD | 1 |
| Carabateas, PM | 1 |
| Williams, GL | 1 |
| Pancic, F | 1 |
| Steinberg, BA | 1 |
| Schmidt, N | 1 |
| Hennig, T | 1 |
| Serwa, RA | 1 |
| Marchetti, M | 1 |
| O'Hare, P | 1 |
| Millhouse, S | 1 |
| Wang, X | 1 |
| Fraser, NW | 2 |
| Faber, L | 1 |
| Block, TM | 1 |
| Okuda, T | 1 |
| Kurokawa, M | 4 |
| Matsuo, K | 1 |
| Honda, M | 1 |
| Niimura, M | 1 |
| Shiraki, K | 4 |
| Lipipun, V | 1 |
| Suttisri, R | 1 |
| Taweechotipatr, P | 1 |
| Pramyothin, P | 1 |
| Hattori, M | 2 |
| Park, HJ | 1 |
| Nakamura, N | 1 |
| Choi, JS | 1 |
| Yamamoto, S | 1 |
| Deckter, LA | 1 |
| Kasai, K | 1 |
| Chiocca, EA | 1 |
| Saeki, Y | 1 |
| Yamauchi, Y | 1 |
| Kiriyama, K | 1 |
| Kimura, H | 1 |
| Nishiyama, Y | 2 |
| Poryo, A | 1 |
| Wigand, R | 2 |
| Burkhardt, U | 1 |
| Svennerholm, B | 2 |
| Ziegler, R | 1 |
| Lycke, E | 3 |
| Blohmé, I | 1 |
| Ahlmén, J | 2 |
| Jeansson, S | 1 |
| Ranch, T | 1 |
| Brynger, H | 2 |
| Ayisi, NK | 2 |
| Gupta, VS | 1 |
| Meldrum, JB | 1 |
| Taneja, AK | 1 |
| Babiuk, LA | 2 |
| Klein, RJ | 6 |
| DeStefano, E | 3 |
| Brady, E | 3 |
| Friedman-Kien, AE | 5 |
| Alenius, S | 3 |
| Scriba, M | 1 |
| Rapp, F | 2 |
| Vahlne, A | 1 |
| Berg, M | 1 |
| Broberg, F | 1 |
| Eklind, K | 1 |
| Lindborg, B | 1 |
| Oberg, B | 2 |
| Fanta, D | 1 |
| Schnipper, LE | 1 |
| Crumpacker, CS | 2 |
| Marlowe, SI | 1 |
| Kowalsky, P | 1 |
| Hershey, BJ | 1 |
| Levin, MJ | 1 |
| Edwards, ML | 1 |
| Ritter, HW | 1 |
| Stemerick, DM | 1 |
| Stewart, KT | 1 |
| Hozumi, T | 1 |
| Tsurita, M | 1 |
| Kadota, S | 1 |
| Namba, T | 1 |
| St Geme, JW | 1 |
| Yellin, PB | 1 |
| Wohlenberg, C | 1 |
| Openshaw, H | 1 |
| Notkins, AL | 1 |
| Cho, CT | 1 |
| Feng, KK | 1 |
| Palmer, AE | 1 |
| London, WT | 1 |
| Sever, JL | 1 |
| Colberg-Poley, AM | 1 |
| Isom, H | 1 |
| McCarty, JR | 1 |
| Jarratt, MT | 1 |
| Streissle, G | 1 |
| Masur, H | 1 |
| Jansen, CL | 1 |
| Maris-Tegeler, WG | 1 |
| Wertheim-van Dillen, PM | 1 |
| Frissen, PH | 2 |
| Weiland, HT | 1 |
| van der Noordaa, J | 1 |
| Birch, CJ | 2 |
| Tyssen, DP | 1 |
| Tachedjian, G | 2 |
| Doherty, R | 1 |
| Hayes, K | 2 |
| Mijch, A | 1 |
| Lucas, CR | 1 |
| Cotte, L | 1 |
| Langlois, M | 1 |
| Trepo, C | 1 |
| Yirrell, DL | 2 |
| Rogers, CE | 2 |
| Blyth, WA | 2 |
| Hill, TJ | 2 |
| Pelosi, E | 1 |
| Hicks, KA | 1 |
| Sacks, SL | 1 |
| Coen, DM | 1 |
| Molina, JM | 1 |
| David, F | 1 |
| Scieux, C | 1 |
| Schnell, L | 1 |
| Gerrier, F | 1 |
| Kateb, M | 1 |
| Morinet, F | 1 |
| Modai, J | 1 |
| Hardy, WD | 1 |
| Arao, Y | 1 |
| Hatano, A | 1 |
| Yamada, M | 1 |
| Uno, F | 1 |
| Nii, S | 1 |
| Moeland, A | 1 |
| Bruun, JN | 1 |
| Arbesfeld, DM | 1 |
| Thomas, I | 1 |
| Jacobson, MA | 2 |
| Gambertoglio, JG | 1 |
| Aweeka, FT | 1 |
| Causey, DM | 1 |
| Portale, AA | 1 |
| Stellbrink, HJ | 1 |
| Albrecht, H | 1 |
| Löning, T | 1 |
| Greten, H | 1 |
| Bevilacqua, F | 1 |
| Marcello, A | 1 |
| Toni, M | 1 |
| Zavattoni, M | 1 |
| Cusini, M | 1 |
| Zerboni, R | 1 |
| Gerna, G | 1 |
| Palù, G | 1 |
| Minor, JR | 1 |
| Baltz, JK | 1 |
| Van Der Pijl, JW | 1 |
| Reiss, P | 1 |
| Hulsebosch, HJ | 1 |
| Van Den Tweel, JG | 1 |
| Lange, JM | 1 |
| Danner, SA | 1 |
| Charmot, G | 1 |
| Ingrand, D | 1 |
| Simon, F | 1 |
| Kernbaum, S | 1 |
| Fegueux, S | 1 |
| De Truchis, P | 1 |
| Coulaud, JP | 1 |
| Safrin, S | 2 |
| Assaykeen, T | 1 |
| Follansbee, S | 1 |
| Mills, J | 3 |
| Ljungman, P | 1 |
| Ellis, MN | 2 |
| Hackman, RC | 1 |
| Shepp, DH | 1 |
| Meyers, JD | 1 |
| Doherty, RR | 1 |
| Gust, ID | 1 |
| Bryson, YJ | 1 |
| Erlich, KS | 1 |
| Koehler, JE | 1 |
| Follansbee, SE | 1 |
| Drennan, DP | 2 |
| Gooze, L | 1 |
| MacPhail, LA | 1 |
| Greenspan, D | 1 |
| Schiødt, M | 1 |
| Chatis, PA | 1 |
| Miller, CH | 1 |
| Schrager, LE | 1 |
| Bean, B | 1 |
| Fletcher, C | 1 |
| Englund, J | 1 |
| Lehrman, SN | 1 |
| Helbig, B | 1 |
| Sauerbrei, A | 1 |
| Klöcking, R | 1 |
| Wutzler, P | 4 |
| Wicht, N | 1 |
| Wiedemann, U | 1 |
| Herrmann, G | 3 |
| Spivack, JG | 1 |
| Kristofferson, A | 1 |
| Ericson, AC | 2 |
| Sohl-Akerlund, A | 1 |
| Datema, R | 2 |
| Reefschläger, J | 2 |
| Thiel, KD | 2 |
| Ulbricht, A | 1 |
| Färber, I | 1 |
| Spruance, SL | 1 |
| Freeman, DJ | 1 |
| Sheth, NV | 1 |
| van Genderen, J | 1 |
| Wolthuis, OL | 1 |
| Ariens, AT | 1 |
| Dolin, R | 1 |
| Mao, JC | 1 |
| Otis, ER | 1 |
| von Esch, AM | 1 |
| Herrin, TR | 1 |
| Fairgrieve, JS | 1 |
| Shipkowitz, NL | 1 |
| Duff, RG | 1 |
| Gupta, SV | 1 |
| Veerisetty, V | 1 |
| Gentry, GA | 1 |
| Larder, BA | 1 |
| Darby, G | 1 |
| Wijnween, AC | 1 |
| Hall, MJ | 1 |
| Harmenberg, J | 1 |
| Abele, G | 1 |
| Wahren, B | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase II Dose-Ranging, Open-Labelled Trial of Foscarnet Salvage Therapy for AIDS Patients With Sight-Threatening CMV Retinitis Who Cannot Be Treated With Ganciclovir Due To Myelosuppression or Treatment Failure[NCT00000691] | Phase 2 | 156 participants | Interventional | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
7 reviews available for phosphonoacetic acid and Herpes Simplex
| Article | Year |
|---|---|
[Herpes simplex].
Topics: Adolescent; Adult; Amantadine; Antigens, Viral; Cell Transformation, Viral; Female; Foscarnet; Herpe | 1981 |
Treatment of experimental latent herpes simplex virus infections with acyclovir and other antiviral compounds.
Topics: Acyclovir; Animals; Antiviral Agents; Culture Techniques; Foscarnet; Ganglia; Guanine; Herpes Simple | 1982 |
Therapeutic control of viral infections: chemotherapy, interferon and gamma globulin.
Topics: Amantadine; Animals; Benzimidazoles; Chickenpox; Cytarabine; gamma-Globulins; Hepatitis, Viral, Huma | 1979 |
[Treatment of herpesvirus infections].
Topics: Acyclovir; Antiviral Agents; Cytomegalovirus Infections; Drug Resistance, Microbial; Foscarnet; Ganc | 1991 |
Cutaneous herpes simplex virus infections.
Topics: Acyclovir; Administration, Oral; Antiviral Agents; Diagnosis, Differential; Drug Resistance, Microbi | 1991 |
Foscarnet sodium.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Cytomegalovirus Infections; Eye Infections, Vi | 1991 |
Promising new antiviral drugs.
Topics: Acyclovir; Animals; Antiviral Agents; Bromodeoxyuridine; Cytomegalovirus Infections; Foscarnet; Ganc | 1988 |
2 trials available for phosphonoacetic acid and Herpes Simplex
| Article | Year |
|---|---|
Foscarnet treatment of acyclovir-resistant herpes simplex virus infection in patients with acquired immunodeficiency syndrome: preliminary results of a controlled, randomized, regimen-comparative trial.
Topics: Acquired Immunodeficiency Syndrome; Acyclovir; Antiviral Agents; Drug Resistance, Microbial; Foscarn | 1992 |
Antiviral chemotherapy and chemoprophylaxis.
Topics: Acyclovir; Adult; Aged; Amantadine; Antiviral Agents; Chickenpox; Clinical Trials as Topic; Cytomega | 1985 |
71 other studies available for phosphonoacetic acid and Herpes Simplex
| Article | Year |
|---|---|
Phosphonoformate and phosphonoacetate derivatives of 5-substituted 2'-deoxyuridines: synthesis and antiviral activity.
Topics: Animals; Antiviral Agents; Bromodeoxyuridine; Cell Line; Chemical Phenomena; Chemistry; Deoxyuridine | 1988 |
Synthesis and antiherpetic activity of some 4-[(aryloxy)alkyl]pyrazoles.
Topics: Animals; Anisoles; Antiviral Agents; Female; Herpes Simplex; Mice; Phenyl Ethers; Pyrazoles; Simplex | 1981 |
Remote Activation of Host Cell DNA Synthesis in Uninfected Cells Signaled by Infected Cells in Advance of Virus Transmission.
Topics: Animals; Azides; Bacterial Proteins; Cell Line; Chlorocebus aethiops; DNA Replication; Herpes Simple | 2015 |
Direct evidence that HSV DNA damaged by ultraviolet (UV) irradiation can be repaired in a cell type-dependent manner.
Topics: Animals; Chlorocebus aethiops; DNA Damage; DNA Repair; DNA-Directed DNA Polymerase; DNA, Viral; Enzy | 2012 |
Suppression of generation and replication of acyclovir-resistant herpes simplex virus by a sensitive virus.
Topics: Acyclovir; Animals; Antiviral Agents; Chlorocebus aethiops; Drug Resistance, Viral; Female; Herpes S | 2004 |
Efficacy of Thai medicinal plant extracts against herpes simplex virus type 1 infection in vitro and in vivo.
Topics: Animals; Antiviral Agents; Chlorocebus aethiops; Drug Resistance, Viral; Herpes Simplex; Herpesvirus | 2003 |
Antiviral activity of the marine alga Symphyocladia latiuscula against herpes simplex virus (HSV-1) in vitro and its therapeutic efficacy against HSV-1 infection in mice.
Topics: Acyclovir; Administration, Oral; Animals; Antiviral Agents; Brain; Chlorocebus aethiops; Disease Mod | 2005 |
Imaging immediate-early and strict-late promoter activity during oncolytic herpes simplex virus type 1 infection and replication in tumors.
Topics: Animals; Antiviral Agents; Cell Line; Chlorocebus aethiops; Gene Expression; Genetic Engineering; Ge | 2006 |
Herpes simplex virus induces extensive modification and dynamic relocalisation of the nuclear mitotic apparatus (NuMA) protein in interphase cells.
Topics: Animals; Antigens, Nuclear; Cell Cycle Proteins; Cell Line, Tumor; Chlorocebus aethiops; DNA-Directe | 2008 |
Cutaneous herpes simplex virus infection of the guinea pig: lack of resistance to acyclovir and phosphonoformic acid after topical treatment.
Topics: Acyclovir; Administration, Topical; Animals; Drug Resistance, Microbial; Drug Therapy, Combination; | 1984 |
Combined chemotherapy of cutaneous herpes simplex infection of the guinea pig.
Topics: Acyclovir; Animals; Antiviral Agents; Arabinonucleosides; Deoxyuridine; Drug Therapy, Combination; F | 1983 |
Neuritic uptake and transport of antiviral drugs modifying herpes simplex virus infection of rat sensory neurons.
Topics: Acyclovir; Animals; Antigens, Viral; Biological Transport; Cells, Cultured; Female; Foscarnet; Gangl | 1984 |
Disseminating herpes simplex infection: primary lesions in urinary bladder and successful treatment with forscarnet sodium.
Topics: Adult; Female; Foscarnet; Herpes Simplex; Humans; Kidney Transplantation; Organophosphorus Compounds | 1984 |
Combination chemotherapy: interaction of 5-methoxymethyldeoxyuridine with adenine arabinoside, 5-ethyldeoxyuridine, 5-iododeoxyuridine, and phosphonoacetic acid against herpes simplex virus types 1 and 2.
Topics: Animals; Antiviral Agents; Deoxyuridine; Dose-Response Relationship, Drug; Drug Resistance, Microbia | 1980 |
Experimental skin infection with an acyclovir resistant herpes simplex virus mutant: response to antiviral treatment and protection against reinfection.
Topics: Acyclovir; Animals; Drug Resistance, Microbial; Female; Ganglia; Guanine; Herpes Simplex; Mice; Mice | 1980 |
Inhibition of herpesvirus multiplication in guinea pig skin by antiviral compounds.
Topics: Animals; Antiviral Agents; Cytarabine; Foscarnet; Guinea Pigs; Herpes Simplex; Idoxuridine; Male; Or | 1980 |
Persistence of herpes simplex virus (HSV) infection in ganglia and peripheral tissues of guinea pigs.
Topics: Animals; Denervation; Female; Ganglia; Ganglia, Spinal; Guinea Pigs; Herpes Simplex; Phosphonoacetic | 1981 |
Repair replication of viral and cellular DNA in herpes simplex virus type 2-infected human embryonic and xeroderma pigmentosum cells.
Topics: Cells, Cultured; DNA Repair; DNA Replication; DNA, Viral; Herpes Simplex; Humans; Phosphonoacetic Ac | 1981 |
Effect of acyclovir on latent herpes simplex virus infections in trigeminal ganglia of mice.
Topics: Acyclovir; Animals; Antiviral Agents; Culture Techniques; Guanine; Herpes Simplex; Mice; Mice, Hairl | 1981 |
Persistent reactivable latent herpes simplex virus infection in trigeminal ganglia of mice treated with antiviral drugs.
Topics: Acyclovir; Animals; Antiviral Agents; Foscarnet; Guanine; Herpes Simplex; Idoxuridine; Male; Mice; M | 1981 |
Pathogenesis of experimental skin infections induced by drug-resistant herpes simplex virus mutants.
Topics: Acyclovir; Animals; Antibodies, Viral; Drug Resistance, Microbial; Female; Guanine; Herpes Simplex; | 1981 |
Therapeutic effects of foscarnet sodium and acyclovir on cutaneous infections due to herpes simplex virus type 1 in guinea pigs.
Topics: Acyclovir; Administration, Topical; Animals; Dose-Response Relationship, Drug; Foscarnet; Guanine; G | 1982 |
Drug-resistant herpes simplex virus in vitro and after acyclovir treatment in an immunocompromised patient.
Topics: Acyclovir; Antiviral Agents; DNA-Directed DNA Polymerase; Drug Resistance, Microbial; Guanine; Herpe | 1982 |
Mannich bases of 4-phenyl-3-buten-2-one: a new class of antiherpes agent.
Topics: Amines; Animals; Butanones; Dose-Response Relationship, Drug; Herpes Simplex; Mannich Bases; Mice; M | 1983 |
Biological characterization of eugeniin as an anti-herpes simplex virus type 1 compound in vitro and in vivo.
Topics: Acyclovir; Animals; Antiviral Agents; Brain; Female; Gallic Acid; Glucosides; Herpes Simplex; Herpes | 2001 |
Latent herpes simplex virus in ganglia of mice after primary infection and reinoculation at a distant site.
Topics: Animals; Antibodies, Viral; Central Nervous System Diseases; Ganglia; Ganglia, Spinal; Herpes Simple | 1978 |
Orofacial herpes simplex virus infection in hairless mice: latent virus in trigeminal ganglia after topical antiviral treatment.
Topics: Administration, Topical; Animals; Antibodies, Viral; Facial Dermatoses; Herpes Simplex; Mice; Mice, | 1978 |
In vitro system for studying the efficacy of antiviral agents in preventing the reactivation of latent herpes simplex virus.
Topics: Animals; Antibodies, Viral; Antiviral Agents; Female; Ganglia; Herpes Simplex; Interferons; Mice; Mi | 1979 |
Synergistic effects of antiviral agents and humoral antibodies in experimental Herpesvirus hominis encephalitis.
Topics: Animals; Antibodies, Viral; Antiviral Agents; Brain; Dose-Response Relationship, Drug; Encephalitis; | 1977 |
Disodium phosphonoacetate in cream base as a possible topical treatment for skin lesions of herpes simplex virus in cebus monkeys.
Topics: Animals; Haplorhini; Herpes Simplex; Ointments; Organophosphorus Compounds; Phosphonoacetic Acid; Pl | 1977 |
Experimental HSV latency using phosphonoacetic acid.
Topics: Cells, Cultured; DNA, Viral; Embryo, Mammalian; Herpes Simplex; Humans; Lung; Organophosphorus Compo | 1979 |
Topical phosphonoacetic acid treatment of cutaneous herpes simplex infections in the guinea pig.
Topics: Animals; Croton Oil; Disease Models, Animal; Drug Evaluation, Preclinical; Female; Guinea Pigs; Herp | 1979 |
Comparative evaluation of antiherpetic drugs in animal experiments.
Topics: Animals; Brain Diseases; Disease Models, Animal; Evaluation Studies as Topic; Herpes Simplex; Immuno | 1979 |
Comparison of the therapeutic effects of five antiviral agents on cutaneous herpesvirus infection in guinea pigs.
Topics: Animals; Antiviral Agents; Cytarabine; Guinea Pigs; Herpes Simplex; Idoxuridine; Phosphonoacetic Aci | 1978 |
Clinical implications of herpesvirus infections in patients with AIDS. Introduction.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Cytomegalovirus Infections; Eye Infections, Vi | 1992 |
[Acyclovir-resistant herpes simplex virus infections in immunocompromised patients].
Topics: Acquired Immunodeficiency Syndrome; Acyclovir; Adult; Antiviral Agents; Bone Transplantation; Drug R | 1992 |
Clinical effects and in vitro studies of trifluorothymidine combined with interferon-alpha for treatment of drug-resistant and -sensitive herpes simplex virus infections.
Topics: Acquired Immunodeficiency Syndrome; Acyclovir; Adult; Antiviral Agents; Combined Modality Therapy; C | 1992 |
Herpes simplex virus infection during foscarnet therapy.
Topics: Acquired Immunodeficiency Syndrome; Adult; Antiviral Agents; Cytomegalovirus Infections; Foscarnet; | 1992 |
Experimental in vivo generation of intertypic recombinant strains of HSV in the mouse.
Topics: Animals; Female; Foscarnet; Ganglia, Sympathetic; Herpes Simplex; Mice; Mice, Inbred Strains; Phosph | 1992 |
Heterogeneity of a herpes simplex virus clinical isolate exhibiting resistance to acyclovir and foscarnet.
Topics: Acyclovir; Animals; Drug Resistance, Microbial; Foscarnet; Genetic Variation; Herpes Simplex; Humans | 1992 |
[Type 1 herpesvirus cutaneo-mucous infection resistant to aciclovir in a HIV infected patient. Clinical and virological study].
Topics: Acyclovir; Adult; Antiviral Agents; Drug Resistance, Microbial; Foscarnet; Herpes Simplex; HIV Infec | 1992 |
Reactivatable latency of three avirulent strains of herpes simplex virus type 1 after intranasal inoculation in mice.
Topics: Acyclovir; Administration, Intranasal; Animals; Butyrates; Butyric Acid; Herpes Simplex; Mice; Phosp | 1991 |
Foscarnet-induced hypocalcemia and effects of foscarnet on calcium metabolism.
Topics: Antiviral Agents; Calcium; Dose-Response Relationship, Drug; Foscarnet; Herpes Simplex; Humans; Hypo | 1991 |
Herpes simplex virus type-2 ulcers resistant to acyclovir in an AIDS patient--successful treatment with foscarnet.
Topics: Acquired Immunodeficiency Syndrome; Acyclovir; Adult; Antiviral Agents; Anus Diseases; Drug Resistan | 1991 |
Acyclovir resistance/susceptibility in herpes simplex virus type 2 sequential isolates from an AIDS patient.
Topics: Acquired Immunodeficiency Syndrome; Acyclovir; Adult; Drug Resistance, Microbial; Follow-Up Studies; | 1991 |
Foscarnet effective in acyclovir-resistant herpes.
Topics: Acquired Immunodeficiency Syndrome; Acyclovir; Antiviral Agents; Drug Resistance, Microbial; Foscarn | 1991 |
Foscarnet and penile ulceration.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Cytomegalovirus Infections; Foscarnet; Herpes | 1990 |
[Aciclovir-resistant herpes simplex virus infection in an immuno-depressed patient. Favourable effect of foscarnet].
Topics: Acyclovir; Antiviral Agents; Drug Resistance, Microbial; Foscarnet; Herpes Simplex; HIV Seropositivi | 1990 |
Heterotypic and homotypic re-inoculation of mice already latently infected with herpes simplex virus type 1.
Topics: Animals; Antiviral Agents; Drug Resistance, Microbial; Female; Foscarnet; Herpes Simplex; Mice; Mice | 1990 |
Foscarnet therapy for acyclovir-resistant mucocutaneous herpes simplex virus infection in 26 AIDS patients: preliminary data.
Topics: Acquired Immunodeficiency Syndrome; Acyclovir; Adult; Drug Resistance, Microbial; Female; Foscarnet; | 1990 |
Acyclovir-resistant herpes simplex virus causing pneumonia after marrow transplantation.
Topics: Acyclovir; Adult; Animals; Antiviral Agents; Bone Marrow Transplantation; Cells, Cultured; Drug Resi | 1990 |
Altered sensitivity to antiviral drugs of herpes simplex virus isolates from a patient with the acquired immunodeficiency syndrome.
Topics: Acquired Immunodeficiency Syndrome; Acyclovir; Adult; Antiviral Agents; Aphidicolin; Deoxyguanosine; | 1990 |
Foscarnet therapy for severe acyclovir-resistant herpes simplex virus type-2 infections in patients with the acquired immunodeficiency syndrome (AIDS). An uncontrolled trial.
Topics: Acquired Immunodeficiency Syndrome; Acyclovir; Adult; Antiviral Agents; Drug Resistance, Microbial; | 1989 |
Acyclovir-resistant, foscarnet-sensitive oral herpes simplex type 2 lesion in a patient with AIDS.
Topics: Acquired Immunodeficiency Syndrome; Acyclovir; Adult; Antiviral Agents; Candidiasis, Oral; Drug Resi | 1989 |
Successful treatment with foscarnet of an acyclovir-resistant mucocutaneous infection with herpes simplex virus in a patient with acquired immunodeficiency syndrome.
Topics: Acquired Immunodeficiency Syndrome; Acyclovir; Adult; Antiviral Agents; Drug Resistance, Microbial; | 1989 |
Progressive mucocutaneous herpes simplex infection due to acyclovir-resistant virus in an immunocompromised patient: correlation of viral susceptibilities and plasma levels with response to therapy.
Topics: Acyclovir; Child; Drug Resistance, Microbial; Herpes Simplex; Humans; Keratitis, Dendritic; Male; Ph | 1987 |
Therapeutic effect of (E)-5-(2-bromovinyl)-2'-deoxyuridine, caffeic acid oxidation product, and trisodiumphosphonoformate on cutaneous herpes simplex virus type 1 infection in guinea pigs.
Topics: Animals; Antiviral Agents; Bromodeoxyuridine; Caffeic Acids; Cinnamates; Female; Foscarnet; Guinea P | 1987 |
Expression of herpes simplex virus type 1 latency-associated transcripts in the trigeminal ganglia of mice during acute infection and reactivation of latent infection.
Topics: Animals; Deoxyribonuclease BamHI; DNA Restriction Enzymes; DNA, Viral; Herpes Simplex; Mice; Novobio | 1988 |
Limited efficacy of inhibitors of herpes simplex virus DNA synthesis in murine models of recrudescent disease.
Topics: Acyclovir; Administration, Oral; Administration, Topical; Animals; Antiviral Agents; Disease Models, | 1988 |
Efficacy of 5-vinyl-1-beta-D-arabinofuranosyluracil (VaraU) against herpes simplex virus type 2 strains in cell cultures and against experimental herpes encephalitis in mice: comparison with acyclovir and foscarnet.
Topics: Acyclovir; Animals; Antiviral Agents; Arabinofuranosyluracil; Cells, Cultured; Encephalitis; Female; | 1987 |
Herpes simplex virus hepatitis in mice: effects of treatment with trisodium phosphonoformate.
Topics: Animals; Antiviral Agents; Disease Models, Animal; Foscarnet; Hepatitis, Viral, Animal; Herpes Simpl | 1985 |
Comparison of foscarnet cream, acyclovir cream, and acyclovir ointment in the topical treatment of experimental cutaneous herpes simplex virus type 1 infection.
Topics: Acyclovir; Administration, Topical; Animals; Female; Foscarnet; Guinea Pigs; Herpes Simplex; Ointmen | 1986 |
The effects of topical foscarnet in a new model of herpes simplex skin infection.
Topics: Administration, Cutaneous; Animals; Antiviral Agents; Disease Models, Animal; Foscarnet; Herpes Simp | 1987 |
Structure-activity studies on phosphonoacetate.
Topics: Amino Acids; Animals; Cells, Cultured; Chemical Phenomena; Chemistry; Culture Techniques; Dermatitis | 1985 |
Combination chemotherapy: interaction of 5-methoxymethyldeoxyuridine with trifluorothymidine, phosphonoformate and acycloguanosine against herpes simplex viruses.
Topics: Acyclovir; Animals; Antiviral Agents; Deoxyuridine; DNA, Viral; Drug Combinations; Drug Resistance, | 1985 |
HSV1-specific thymidylate kinase activity in infected cells.
Topics: Acyclovir; Animals; Bromodeoxyuridine; Cells, Cultured; Cricetinae; Deoxyuridine; Drug Resistance, M | 1985 |
Selection and characterisation of acyclovir-resistant herpes simplex virus type 1 mutants inducing altered DNA polymerase activities.
Topics: Acyclovir; Animals; Cell Line; Cricetinae; DNA-Directed DNA Polymerase; Drug Resistance, Microbial; | 1985 |
Clinical experiences with phosphonoformate (foscarnet) treatment of viral diseases following renal transplantation.
Topics: Adult; Aged; Antiviral Agents; Cytomegalovirus Infections; Female; Foscarnet; Herpes Simplex; Herpes | 1985 |
Treatment of experimental herpes simplex virus type 1 encephalitis in mice with (E)-5-(2-bromovinyl)- and 5-vinyl-1-beta-D-arabinofuranosyluracil: comparison with bromovinyl-deoxyuridine and acyclovir.
Topics: Acyclovir; Animals; Arabinofuranosyluracil; Bromodeoxyuridine; Cells, Cultured; Encephalitis; Female | 1986 |
Anti-herpes virus combinations in relation to drug resistance.
Topics: Acyclovir; Adenosine Deaminase Inhibitors; Animals; Antiviral Agents; Diphosphates; Drug Resistance, | 1986 |
Nucleoside pools of acyclovir-treated herpes simplex type 1 infected cells.
Topics: Acyclovir; Animals; Cells, Cultured; Chlorocebus aethiops; Foscarnet; Herpes Simplex; Humans; Kineti | 1985 |